Abstract
Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have